Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

AVARA Rx vs Medro

AVARA Rx
Graded #263

Lower grade

vs+0.8000000000000043
Medro
Graded #252

Higher grade

The verdict

Medro takes it — 63.6/100 to 62.8/100, but only just.

Medro grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Medro (Medro Health Technologies, Inc.) is a telehealth brand whose GLP-1 program offers compounded semaglutide and tirzepatide, plus brand-name GLP-1s when eligible, via a partner medical group and… AVARA Rx is close behind and may still be the better fit — see the factor split below.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueMedro +7
43
50
Dose & formulationEven
77
77
Clinical oversightAVARA Rx +5
76
71
Labs & monitoringEven
52
52
FulfillmentMedro +15
77
92
Contract termsAVARA Rx +22
55
33
AVARA Rx · left barMedro · right bar

The numbers

MetricAVARA RxMedro
WeighScore62.8/10063.6/100
GradeCC
Scorecard rank#263#252
Semaglutide$229/mo (starting dose, compounded)$199/mo (compounded)
Tirzepatide$279/mo (starting dose, compounded)$299/mo (compounded)
CoverageAll 50 statesAll 50 states
Brand-name accessYesYes
Oral / sublingualInjection onlyInjection only
AVARA Rx

Graded #263 · C

Strengths

  • Names its pharmacy partner (DiRx Health, Ft Lauderdale FL) — buyers can independently verify its licensure
  • Names its clinical network (Beluga Health) — you can research the platform handling your prescriptions
  • All 50 states explicitly listed on the FAQ — uncommon vs peers that just say 'nationwide'
  • Patient-friendly refunds — full refund if a provider disqualifies you, partial if a weaker dose is prescribed
  • LegitScript verification badge displayed; pharmacy claims NABP-accredited facilities

Where it loses points

  • Operating legal entity not disclosed — only a Sheridan, WY registered-agent-style address surfaced
  • Dose pricing not itemized — only 'starting at $229' semaglutide and 'starting at $279' tirzepatide
  • LegitScript certification number not shown — badge only, so no direct lookup
  • No named medical director (Beluga Health is the network, not a named MD)
  • Lab work requirements not specified, and consultation fee not broken out from medication cost
Medro

Graded #252 · C

Strengths

  • Covers both compounded semaglutide and tirzepatide and can prescribe brand-name GLP-1s when clinically appropriate.
  • LegitScript-certified (seal #50716646), available in all 50 states, with tiered pricing shown before checkout.
  • No membership fee and free expedited shipping on all orders; online intake with no appointment required in many cases.
  • Prices drop with longer commitments (semaglutide to $149/mo, tirzepatide to $224/mo on a 12-month plan).

Where it loses points

  • Does not name its compounding pharmacy or its clinical partner medical group, so the fulfillment chain is not verifiable.
  • Pricing is described as illustrative and may change by dose, pharmacy availability, and eligibility — final cost shows only at checkout.
  • Very new brand (2026, trademark pending) spanning many verticals, with a short track record in GLP-1 care.
  • Compounded medications are not FDA-approved or therapeutically equivalent to Ozempic, Wegovy, Mounjaro, or Zepbound.

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard